Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;55(3):255-6.

Vaginal yeast infections during pregnancy

Derrick Soong  1 , Adrienne Einarson
Affiliations
Review

Vaginal yeast infections during pregnancy

Derrick Soong et al. Can Fam Physician. 2009 Mar.

Abstract
in English, French

Question: My pregnant patients often present with symptomatic vaginal yeast infections. Are the medications commonly used for the management of yeast infections safe to use during pregnancy?

Answer: Existing data indicate that exposure to oral and topical antifungals, topical antiseptics, or corticosteroids during pregnancy is not associated with increased risk of major malformations. Topical azole antifungals are the recommended treatment during pregnancy for at least 7 days owing to increased efficacy. Topical corticosteroids can be used for symptomatic relief.

QUESTION Il arrive souvent que des patientes enceintes me consultent pour des infections vaginales symptomatiques à levures. Les médicaments habituellement utilisés pour le traitement des infections à levures sont-ils sans danger durant la grossesse?

RÉPONSE Les données actuelles indiquent que l’exposition aux antifongiques topiques ou par voie orale, aux antiseptiques topiques ou aux corticostéroïdes durant la grossesse n’est pas associée à un risque accru de malformations importantes. On recommande comme traitement pendant la grossesse des antifongiques topiques azolés pendant au moins 7 jours étant donné leur plus grande efficacité. Les corticostéroïdes peuvent être utilisés pour le soulagement des symptômes.

PubMed Disclaimer

References

    1. Das Neves J, Pinto E, Teixeira B, Dias G, Rocha P, Cunha T, et al. Local treatment of vulvovaginal candidosis: general and practical considerations. Drugs. 2008;68(13):1787–802. - PubMed
    1. Ferrer J. Vaginal candidosis: epidemiological and etiological factors. Int J Gynaecol Obstet. 2000;71(Suppl 1):S21–7. - PubMed
    1. Eschenbach DA. Chronic vulvovaginal candidiasis. N Engl J Med. 2004;351(9):851–2. - PubMed
    1. Monif GR, Baker DA. Candida albicans. In: Monif GR, Baker DA, editors. Infectious diseases in obstetrics and gynecology. 5th ed. New York, NY: Parthenon Press; 2003. pp. 405–21.
    1. Baron EJ, Cassell GH, Duffy LB, Eschenbach JR, Greenwood SM, Harvey NE, et al. Laboratory diagnosis of female genital tract infections. In: Baron EJ, editor. Cumulative techniques and procedures in clinical microbiology (Cumitech) 17A. Washington, DC: ASM Press; 1993. pp. 1–28.

MeSH terms